Cybin D/B/A Helus Pharma (HELP) Stock Analysis
A live, multi-source view of Cybin D/B/A Helus Pharma (HELP): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Cybin D/B/A Helus Pharma
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Sector: Healthcare · Industry: Biotechnology · Canada · 100 employees · helus.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Cybin D/B/A Helus Pharma (HELP) had a market capitalization of $892.8M (forward -6.7) and a beta of 0.63; the shares traded in a 52-week range of $3.76 – $14.35 (87.7% over the year).
- Market cap
- $892.8M
- Enterprise value
- $1.61B
- Forward P/E
- -6.7
- Price / book
- 227.51
- EPS (trailing)
- $-4.06
- EPS (forward)
- $-1.83
- Payout ratio
- 0.0%
- 52-week range
- $3.76 – $14.35
- 52-week change
- 87.7%
- Beta
- 0.63
- Average volume
- 1.7M
- Shares outstanding
- 73.1M
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Cybin D/B/A Helus Pharma (HELP) last closed at $12.84 (the last completed close before that scan).
Technicals at the scan: RSI 60 (neutral territory), price +3.6% versus its 20-day average, 20-day versus 50-day average spread +27.5%, MACD histogram -0.13.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 90% bullish; Reddit mentions +200% over 24 hours; analyst consensus score 75/100.
Next scheduled company event: in 62 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for HELP in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
HELP has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Cybin D/B/A Helus Pharma (HELP) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell HELP.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.